Alembic Pharmaceuticals secures USFDA approval for Dapagliflozin Tablets ANDA
Approval grants eligibility for 180-day shared generic drug exclusivity
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Lupin receives Great Place To Work certification across global operations
Recognition based on study covering subsidiaries and employee participation
CuraTeQ Biologics reports Phase 3 results for BP11 biosimilar to Xolair
Study meets primary endpoints in chronic spontaneous urticaria across Europe and India
Bayer revises access model for Eylea 2mg in India to expand patient eligibility
Company aims to lower upfront cost to support early treatment initiation for retinal diseases
Leading people in the age of AI
As AI reshapes pharma, HR leadership is being drawn into a deeper question that goes beyond technology to the future of people and…
Patent expiries ahead, is India Pharma Inc ready?
Beyond the semaglutide momentum, a larger wave of patent expiries is set to unfold between 2026 and 2032. For Indian pharma, the…
Emcure Pharmaceuticals revises price of Poviztra semaglutide injection in India
Weight management drug to be available from Rs 3,999 per month from April 3, 2026
Mumbai Experience Center reflects Agilent’s continued commitment to India
Bharat Bhardwaj, Vice President, Asia Pacific, Agilent Technologies spoke to Viveka Roychowdhury on why Agilent has been…
Lupin completes acquisition of VISUfarma
The integration of VISUfarma has expanded Lupin’s ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma,…
Glenmark to manage end-to-end commercialisation and distribution for RYALTRIS in US
RYALTRIS is Glenmark’s first innovative product introduced into the US market